BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects. Early clinical testing by Serentrix LLC has shown that the...
BioCentury | Nov 30, 2018
Company News

Pfizer extends Lyrica exclusivity by six months in U.S.

Pfizer Inc. (NYSE:PFE) said FDA granted pediatric exclusivity to its blockbuster neurology drug Lyrica pregabalin, extending the product's patent protection by six months to June 30, 2019. Lyrica is approved in the U.S. to treat...
BioCentury | Oct 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Sep 10, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the USP5-CACNA1H interaction could help treat postsurgical pain. In a mouse model of incisional pain, shRNA targeting of USP5 or systemic knockout of CACNA1H decreased mechanical allodynia compared with...
BioCentury | Feb 2, 2018
Product R&D

It’s the assay...

Genentech and Xenon have reported that the key to finding a selective Nav1.7 blocker is devising a better screen, not using a bigger compound library. By retooling a commonly used assay, the partners identified a...
BioCentury | Dec 13, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Ocular hypertension Mouse studies suggest inhibiting CACNA2D1 could help treat ocular hypertension. In a mouse model of ocular hypertension, Lyrica pregabalin, which inhibits CACNAD21, decreased intraocular pressure compared with no treatment. Next steps could...
BioCentury | Sep 14, 2017
Strategy

Numerate’s Intelligence

With three new partnerships formed since June, Numerate Inc. is picking up steam and demonstrating that industry and academic groups alike are finding utility in its AI platform, which can build robust predictive models for...
BioCentury | Jun 15, 2017
Translation in Brief

MicroRNA's big role in pain

...involved in pain responses, including calcium channel voltage-dependent α 2 δ subunits 1 (CACNAD1) and CACNA2D2...
BioCentury | Feb 16, 2017
Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Neurology

INDICATION: Epilepsy Cell culture and rat studies identified a benzodiazepine-based triple-inhibitor of CACNA1G , CACNA1H and CACNA1I that could help treat epilepsy. Chemical synthesis and testing in HEK cells expressing the three calcium channels identified a...
Items per page:
1 - 10 of 32